

Sharon L Walmsley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4291504/sharon-l-walmsley-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

259 papers	10,730 citations	45 h-index	99 g-index
267 ext. papers	12,087 ext. citations	7.2 avg, IF	5.44 L-index

#	Paper	IF	Citations
259	Neighbourhood-level material deprivation and response to combination antiretroviral therapy in the Canadian Observational Cohort (CANOC): a longitudinal cohort study.. <i>CMAJ Open</i> , 2022 , 10, E183-E189	2.5	0
258	Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV/HCV co-infected population in Canada. <i>Antiviral Therapy</i> , 2022 , 27, 135965352110676	1.6	0
257	Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.. <i>International Journal of Drug Policy</i> , 2022 , 103, 103627	5.5	0
256	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.. <i>Dermatology and Therapy</i> , 2022 , 12, 1073	4	0
255	Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?. <i>Clinical Infectious Diseases</i> , 2021 , 73, 468-477	11.6	5
254	The Dietary Inflammatory Index Is Not Associated With Gut Permeability or Biomarkers of Systemic Inflammation in HIV Immunologic Non-responders. <i>Frontiers in Nutrition</i> , 2021 , 8, 736816	6.2	0
253	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , 2021 , 22, 224	2.8	4
252	Estimating an individual-level deprivation index for HIV/HCV coinfecting persons in Canada. <i>PLoS ONE</i> , 2021 , 16, e0249836	3.7	0
251	Patient perspectives on the implementation of routinised syphilis screening with HIV viral load testing: Qualitative process evaluation of the Enhanced Syphilis Screening Among HIV-positive Men trial. <i>BMC Health Services Research</i> , 2021 , 21, 625	2.9	2
250	Routinised Syphilis Screening among Men Living with HIV: A stepped wedge cluster randomised controlled trial. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	2
249	The Intersection of HIV and Syphilis: Update on the Key Considerations in Testing and Management. <i>Current HIV/AIDS Reports</i> , 2021 , 18, 280-288	5.9	3
248	Activation and gut-homing of peripheral T cells in HIV immunologic non-responders despite long term viral suppression. <i>PLoS ONE</i> , 2021 , 16, e0254149	3.7	1
247	Urinary symptoms and quality of life in women living with HIV: a cross-sectional study. <i>International Urogynecology Journal</i> , 2021 , 32, 353-358	2	1
246	Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 729-737	5.1	4
245	Exploring the impact of HIV infection and antiretroviral therapy on placenta morphology. <i>Placenta</i> , 2021 , 104, 102-109	3.4	2
244	Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015. <i>Health Science Reports</i> , 2021 , 4, e358	2.2	0
243	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.. <i>BMJ Open</i> , 2021 , 11, e054208	3	2

242	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. <i>Vaccine</i> , 2020 , 38, 3073-3078	4.1	0
241	Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020 , 382, 1124-1135	59.2	108
240	Plea for multitargeted interventions for severe COVID-19. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1122-1123	1.5	15
239	Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination. <i>International Journal of Gynecology and Obstetrics</i> , 2020 , 150, 108-115	4	2
238	Pilot study assessing the Rotterdam Healthy Aging Score in a cohort of HIV-positive adults in Toronto, Canada. <i>Aids</i> , 2020 , 34, 859-867	3.5	2
237	Deciphering the serological response to syphilis treatment in men living with HIV. <i>Aids</i> , 2020 , 34, 2089-2096	3.6	4
236	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. <i>Lancet HIV, the</i> , 2020 , 7, e16-e26	7.8	25
235	Brief Report: Persistence of Non-Vaccine Oncogenic HPV Genotypes in Quadrivalent HPV-Vaccinated Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 83, 230-234	3.1	1
234	Protecting Frontline Health Care Workers from COVID-19 with Hydroxychloroquine Pre-exposure Prophylaxis: A structured summary of a study protocol for a randomised placebo-controlled multisite trial in Toronto, Canada. <i>Trials</i> , 2020 , 21, 647	2.8	6
233	Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020 , 71, 363-371	11.6	11
232	Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial. <i>PLoS ONE</i> , 2019 , 14, e0221653	3.7	1
231	Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz055	1	9
230	The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019 , 68, 788-794	11.6	18
229	Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. <i>AIDS Research and Human Retroviruses</i> , 2019 , 35, 985-998	1.6	8
228	Alendronate/Vitamin D for attenuating bone mineral density loss during antiretroviral initiation: a pilot randomized controlled trial. <i>HIV Research and Clinical Practice</i> , 2019 , 20, 140-150	1.7	1
227	Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 503-513	3.1	13
226	Trends in cause-specific mortality in HIV-hepatitis C coinfection following hepatitis C treatment scale-up. <i>Aids</i> , 2019 , 33, 1013-1022	3.5	11
225	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019 , 393, 143-155	40	175

224	Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. <i>International Journal of Drug Policy</i> , 2019 , 65, 41-49	5.5	10
223	Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 480-488	5.1	0
222	Factors Associated With 30-Day Mortality Rate in Respiratory Infections Caused by Streptococcus pneumoniae. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1282-1285	11.6	2
221	Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients. <i>Aids</i> , 2018 , 32, 751-759	3.5	7
220	Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 595-597	3.4	6
219	Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. <i>Drug and Alcohol Dependence</i> , 2018 , 185, 374-380	4.9	5
218	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018 , 5, e211-e220	7.8	80
217	High retention in HIV care at a tertiary care centre in Toronto, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018 , 30, 246-254	2.2	1
216	Elevated Levels of Estradiol in Human Immunodeficiency Virus-Infected Pregnant Women on Protease Inhibitor-Based Regimens. <i>Clinical Infectious Diseases</i> , 2018 , 66, 420-427	11.6	11
215	Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 1507-1514	3.4	15
214	Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer. <i>Aids</i> , 2018 , 32, 2640-2642	3.5	4
213	Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada. <i>Journal of the International AIDS Society</i> , 2018 , 21, e25197	5.4	9
212	Medication nonadherence, multitablet regimens, and food insecurity are key experiences in the pathway to incomplete HIV suppression. <i>Aids</i> , 2018 , 32, 1323-1332	3.5	8
211	Viral suppression and viral rebound among young adults living with HIV in Canada. <i>Medicine (United States)</i> , 2018 , 97, e10562	1.8	14
210	Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. <i>AIDS and Behavior</i> , 2017 , 21, 792-802	4.3	25
209	Exploring the Factors Considered by People Living with HIV and Their Partners during Preconception. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017 , 16, 239-246	1.7	4
208	Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study. <i>HIV Clinical Trials</i> , 2017 , 18, 28-38		9
207	Envisioning Women-Centered HIV Care: Perspectives from Women Living with HIV in Canada. <i>Women's Health Issues</i> , 2017 , 27, 721-730	2.6	37

206	A cross-sectional population-based study of breast cancer screening among women with HIV in Ontario, Canada. <i>CMAJ Open</i> , 2017 , 5, E673-E681	2.5	5
205	The Canadian HIV and aging cohort study - determinants of increased risk of cardio-vascular diseases in HIV-infected individuals: rationale and study protocol. <i>BMC Infectious Diseases</i> , 2017 , 17, 611-4	1.4	26
204	Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. <i>HIV/AIDS - Research and Palliative Care</i> , 2017 , 9, 51-61	1.2	4
203	Injection Drug Use, Unemployment, and Severe Food Insecurity Among HIV-HCV Co-Infected Individuals: A Mediation Analysis. <i>AIDS and Behavior</i> , 2017 , 21, 3496-3505	4.3	5
202	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017 , 4, e536-e546	7.8	67
201	The Use of Multistate Models to Examine Associations of Stress and Adherence With Transitions Among HIV Care States Observed in a Clinical HIV Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 76, 303-310	3.1	4
200	Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. <i>Aids</i> , 2017 , 31, 175-176	3.5	11
199	Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. <i>BMC Infectious Diseases</i> , 2017 , 17, 80	4	5
198	Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2017 , 17, 246	4	18
197	Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 266	4	3
196	Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV. <i>Clinical Infectious Diseases</i> , 2017 , 64, 1154-1162	11.6	45
195	Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. <i>BMJ Open</i> , 2017 , 7, e017391	3	5
194	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017 , 12, e0176282	3.7	5
193	Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs. <i>Clinical Infectious Diseases</i> , 2016 , 62, 139-47	11.6	69
192	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016 , 2, 67-77	2.8	4
191	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. <i>Vaccine</i> , 2016 , 34, 4799-806	4.1	25
190	The Association Between HIV Disclosure Status and Perceived Barriers to Care Faced by Women Living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/Canada. <i>AIDS Patient Care and STDs</i> , 2016 , 30, 435-44	5.8	14
189	Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2016 , 2, 49	1.9	7

188	A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 73, 531-539	3.1	6
187	Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials. <i>HIV Clinical Trials</i> , 2016 , 17, 147-57		27
186	Responder Interferon γ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus Coinfection. <i>Journal of Infectious Diseases</i> , 2016 , 214, 80-6	7	9
185	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. <i>Clinical Infectious Diseases</i> , 2016 , 62, 919-926	11.6	61
184	Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons. <i>Clinical Infectious Diseases</i> , 2016 , 62, 242-249	11.6	7
183	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. <i>Open Forum Infectious Diseases</i> , 2016 , 3, ofw050	1	12
182	HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2771-81	5.9	36
181	Backbones versus core agents in initial ART regimens: one game, two players. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 856-61	5.1	14
180	Low Prolactin and High 20-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2016 , 213, 1532-40	7	16
179	Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge design. <i>Implementation Science</i> , 2016 , 11, 8	8.4	8
178	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. <i>PLoS ONE</i> , 2016 , 11, e0148231	3.7	58
177	What's new for antiretroviral treatment in women with HIV. <i>Journal of Virus Eradication</i> , 2016 , 2, 67-77	2.8	1
176	Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfecting patients. <i>Aids</i> , 2016 , 30, 1403-311	3.5	6
175	Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 72, 153-61	3.1	13
174	Which HIV patients should be screened for osteoporosis: an international perspective. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 268-76	4.2	13
173	Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016 , 28, 954-62	2.2	14
172	Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 6496-512	6.3	5
171	Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naïve HIV-infected individuals in three randomized trials. <i>Aids</i> , 2015 , 29, 167-74	3.5	46

170	Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv036	1	3
169	Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity. <i>Open Forum Infectious Diseases</i> , 2015 , 2, ofv059	1	5
168	Contraceptive options for HIV-positive women: making evidence-based, patient-centred decisions. <i>HIV Medicine</i> , 2015 , 16, 329-36	2.7	2
167	Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 3547-55	4.4	61
166	Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. <i>PLoS ONE</i> , 2015 , 10, e0129868	3.7	5
165	ACP Journal Club: review: Xpert MTB/RIF assay detects extrapulmonary TB in lymph nodes and CSF, but not pleural fluid. <i>Annals of Internal Medicine</i> , 2015 , 162, JC11	8	3
164	Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 70, 515-9	3.1	141
163	Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 276-81	1.6	5
162	HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. <i>Journal of Infectious Diseases</i> , 2015 , 211, 10-8	7	71
161	Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfecting patients after hepatitis C therapy: a prospective cohort study. <i>HIV Clinical Trials</i> , 2015 , 16, 100-10		18
160	Raltegravir as antiretroviral therapy in HIV/AIDS. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 395-405	4	9
159	The importance of motherhood in HIV-positive women of reproductive age in Ontario, Canada. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014 , 26, 777-84	2.2	22
158	Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. <i>Clinical Infectious Diseases</i> , 2014 , 59, 944-52	11.6	39
157	High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. <i>Journal of Clinical Immunology</i> , 2014 , 34, 655-62	5.7	6
156	In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents. <i>Pharmaceutical Research</i> , 2014 , 31, 2404-19	4.5	8
155	A systematic review of the use of atazanavir in women infected with HIV-1. <i>Antiviral Therapy</i> , 2014 , 19, 293-307	1.6	4
154	Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. <i>Aids</i> , 2014 , 28, 717-25	3.5	32
153	Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-naïve persons with HIV. <i>PLoS ONE</i> , 2014 , 9, e85607	3.7	8

152	Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfecting individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. <i>HIV Clinical Trials</i> , 2014 , 15, 161-75		7
151	Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. <i>Mediators of Inflammation</i> , 2014 , 2014, 803095	4.3	6
150	Antiretroviral therapy is not associated with reduced herpes simplex virus shedding in HIV coinfecting adults: an observational cohort study. <i>BMJ Open</i> , 2014 , 4, e004210	3	20
149	Self-Reported Preconception Care of HIV-Positive Women of Reproductive Potential: A Retrospective Study. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014 , 13, 424-33	1.7	15
148	Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). <i>Aids</i> , 2014 , 28, 1957-65	3.5	42
147	Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. <i>Pharmaceutical Research</i> , 2013 , 30, 1050-64	4.5	54
146	Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. <i>BMC Medical Research Methodology</i> , 2013 , 13, 31	4.7	24
145	Management of persons infected with human immunodeficiency virus requiring admission to the intensive care unit. <i>Critical Care Clinics</i> , 2013 , 29, 603-20	4.5	6
144	Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. <i>Annals of Pharmacotherapy</i> , 2013 , 47, 1429-39	2.9	73
143	A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfecting adults on suppressive antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1331-8	11.6	26
142	Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013 , 207, 740-8	7	227
141	Variation between Canadian centres in the uptake of treatment for hepatitis C by patients coinfecting with HIV: a prospective cohort study. <i>CMAJ Open</i> , 2013 , 1, E106-14	2.5	12
140	Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. <i>Clinical Infectious Diseases</i> , 2013 , 57, 448-57	11.6	9
139	Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. <i>Journal of Infectious Diseases</i> , 2013 , 208, 454-62	7	82
138	Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. <i>Clinical Infectious Diseases</i> , 2013 , 57, 663-70	11.6	49
137	Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. <i>New England Journal of Medicine</i> , 2013 , 369, 1807-18	59.2	549
136	Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfecting cohort. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1339-42	11.6	3
135	Caring for women living with HIV: gaps in the evidence. <i>Journal of the International AIDS Society</i> , 2013 , 16, 18509	5.4	44

134	Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2013 , 18, 717-21	1.6	9
133	A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. <i>AIDS Patient Care and STDs</i> , 2012 , 26, 532-40	5.8	23
132	Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1579-83	1.6	9
131	Recent immigrants show improved clinical outcomes at a tertiary care HIV clinic. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2012 , 23, 9-14	2.6	11
130	Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. <i>Virus Adaptation and Treatment</i> , 2012 , 51		
129	CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management. <i>Current Infectious Disease Reports</i> , 2012 , 14, 435-44	3.9	14
128	The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?. <i>Journal of Infectious Diseases</i> , 2012 , 205, 1534-8	7	14
127	Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1568-74	11.6	13
126	High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N12009 and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		21
125	Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the Gemini study. <i>HIV Clinical Trials</i> , 2012 , 13, 111-7		
124	Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2012 , 26, 1789-94	3.5	16
123	High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. <i>HIV Clinical Trials</i> , 2012 , 13, 23-32		11
122	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <i>Lancet, The</i> , 2011 , 378, 238-46	4 ⁰	31 ⁸
121	Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. <i>HIV Clinical Trials</i> , 2011 , 12, 89-103		25
120	Once daily dosing improves adherence to antiretroviral therapy. <i>AIDS and Behavior</i> , 2011 , 15, 1397-409	4.3	23
119	Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naïve HIV-infected patients initiating therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, 38-46	3.1	13
118	No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. <i>Aids</i> , 2011 , 25, 207-10	3.5	25
117	Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. <i>PLoS ONE</i> , 2011 , 6, e17758	3.7	35

116	Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2010 , 21, 159-72	2.6	2
115	Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. <i>International Journal of Epidemiology</i> , 2010 , 39, 1162-9	7.8	79
114	Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naïve subjects with CCR5-tropic HIV-1 infection. <i>Journal of Infectious Diseases</i> , 2010 , 201, 803-13	7	216
113	Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. <i>Journal of Infectious Diseases</i> , 2010 , 201, 590-9	7	36
112	Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy. <i>HIV Clinical Trials</i> , 2010 , 11, 340-50		18
111	Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. <i>Aids</i> , 2010 , 24, 1091-4	3.4	27
110	Response to Stegmann s, et Al. [J. Clin. Virol. 47 (1) (2010) 79-81]. <i>Journal of Clinical Virology</i> , 2010 , 47, 297-8	14.5	
109	Design and methods of the MAINTAIN study: a randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection. <i>Contemporary Clinical Trials</i> , 2010 , 31, 604-13	1.3	6
108	Factors associated with HIV-positive women carrying pregnancies to term. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2010 , 32, 756-62	1.3	0
107	A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipodystrophy. <i>HIV Clinical Trials</i> , 2010 , 11, 39-50		26
106	A CD4+ cell count . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 451-9	3.1	37
105	Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. <i>BMC Infectious Diseases</i> , 2010 , 10, 40	4	14
104	Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. <i>Trials</i> , 2010 , 11, 113	2.8	3
103	Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study. <i>PLoS ONE</i> , 2009 , 4, e7925	3.7	116
102	Seroprevalence and risk factors for herpes simplex virus infection in a population of HIV-infected patients in Canada. <i>Sexually Transmitted Diseases</i> , 2009 , 36, 165-9	2.4	22
101	Etravirine for HIV-1: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009 , 8, 354-63		3
100	Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. <i>Aids</i> , 2009 , 23, 429-31	3.5	9
99	Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 367-74	3.1	83

98	First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach. <i>Current Opinion in HIV and AIDS</i> , 2009 , 4, 493-8	4.2	2
97	Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 555-70	27.4	739
96	Reassessment of enfuvirtide role in the management of HIV-1 infection. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2349-62	4	9
95	A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy. <i>HIV Clinical Trials</i> , 2008 , 9, 314-23		10
94	Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 47, 429-40	3.1	23
93	Combining protease inhibitors with new drug classes in treatment-experienced patients. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 647-52	4.2	1
92	Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. <i>HIV Clinical Trials</i> , 2008 , 9, 73-82		9
91	TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2007 , 21, 533-43	5.8	43
90	Systematic review of strategies to measure HIV-related diarrhea. <i>HIV Clinical Trials</i> , 2007 , 8, 155-63		7
89	An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational database. <i>HIV Clinical Trials</i> , 2007 , 8, 311-9		4
88	Evaluation of Stool frequency and stool form as measures of HIV-related diarrhea. <i>HIV Clinical Trials</i> , 2007 , 8, 421-8		7
87	A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. <i>Journal of Infectious Diseases</i> , 2007 , 195, 1754-61	7	36
86	Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 3821-3	9.7	39
85	Protease inhibitor-based regimens for HIV therapy: safety and efficacy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45 Suppl 1, S5-13; quiz S28-31	3.1	24
84	Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. <i>Aids</i> , 2007 , 21, 2245-8	3.5	6
83	A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 45, 418-25	3.1	10
82	One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. <i>Archives of Internal Medicine</i> , 2007 , 167, 1312-20		155
81	Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen. <i>HIV Clinical Trials</i> , 2007 , 8, 259-68		3

80	Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. <i>Expert Review of Anti-Infective Therapy</i> , 2007 , 5, 13-28	5.5	9
79	The clinical cost of delays in switching therapy. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2007 , 18 Suppl A, 5A-7A	2.6	
78	Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors. <i>HIV Clinical Trials</i> , 2006 , 7, 107-15		4
77	Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1337-46	11.6	73
76	Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. <i>AIDS Patient Care and STDs</i> , 2006 , 20, 245-57	5.8	11
75	Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMV primers and the Linear array HPV genotyping test. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 1998-2006	9.7	122
74	Is chromium an important element in HIV-positive patients with metabolic abnormalities? An hypothesis generating pilot study. <i>Journal of the American College of Nutrition</i> , 2006 , 25, 56-63	3.5	3
73	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <i>Lancet The</i>	40	283
72	Organ transplantation in HIV-infected individuals: The time has come - should there be criteria?. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006 , 17, 8-10	2.6	
71	Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2006 , 17, 155-63	2.6	3
70	The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial. <i>Archives of Internal Medicine</i> , 2006 , 166, 1178-83		5
69	Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. <i>HIV Clinical Trials</i> , 2006 , 7, 1-9		15
68	Lipodystrophy severity does not contribute to HAART nonadherence. <i>AIDS and Behavior</i> , 2006 , 10, 273-74	4.3	7
67	Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 404-12	3.1	131
66	Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. <i>Journal of Clinical Densitometry</i> , 2005 , 8, 293-7	3.5	28
65	Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study. <i>HIV Clinical Trials</i> , 2005 , 6, 203-12		9
64	The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. <i>Quality of Life Research</i> , 2005 , 14, 981-90	3.7	33
63	Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. <i>Journal of Clinical Oncology</i> , 2005 , 23, 990-8	2.2	44

62	CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1407-11	7	15
61	Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. <i>Clinical Infectious Diseases</i> , 2005 , 41, 527-34	11.6	33
60	Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. <i>HIV Clinical Trials</i> , 2005 , 6, 127-35		15
59	Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 413-21	3.1	69
58	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005 , 10, 735-743	1.6	30
57	Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2004 , 15, 327-35	2.6	7
56	SARS outbreak in the Greater Toronto Area: the emergency department experience. <i>Cmaj</i> , 2004 , 171, 1342-4	3.5	18
55	A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). <i>HIV Clinical Trials</i> , 2004 , 5, 7-18		10
54	Polypharmacy in HIV: impact of data source and gender on reported drug utilization. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 568-86	5.8	27
53	Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naïve patients. <i>Journal of Infectious Diseases</i> , 2004 , 190, 280-4	7	26
52	Treatment of HIV infection in pregnant women: antiretroviral management options. <i>Drugs</i> , 2004 , 64, 471-88	12.1	10
51	Medicinal and recreational marijuana use by patients infected with HIV. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 215-28	5.8	83
50	Rosiglitazone for HIV-1 lipodystrophy. <i>Lancet, The</i> , 2004 , 363, 1828-9; author reply 1829	40	3
49	Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. <i>Lancet, The</i> , 2004 , 364, 1036-7	40	5
48	Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. <i>Cmaj</i> , 2004 , 170, 47-54	3.5	51
47	Structured interruption of treatment hastened disease progression in multidrug-resistant HIV. <i>ACP Journal Club</i> , 2004 , 140, 64		
46	Structured interruption of treatment hastened disease progression in multidrug-resistant HIV. <i>ACP Journal Club</i> , 2004 , 140, 64		
45	Predictive Value of HIV-1 Protease Genotype and Virtual Phenotype on the Virological Response to Lopinavir/Ritonavir-Containing Salvage Regimens. <i>Antiviral Therapy</i> , 2004 , 9, 595-602	1.6	14

44	Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. <i>New England Journal of Medicine</i> , 2003 , 348, 2175-85	59.2	763
43	Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2801-9	27.4	960
42	Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. <i>HIV Clinical Trials</i> , 2003 , 4, 301-10		11
41	Inclusion body myositis. <i>Aids</i> , 2003 , 17, 1266-1267	3.5	7
40	Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. <i>AIDS Patient Care and STDs</i> , 2003 , 17, 155-68	5.8	54
39	The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults. <i>Expert Review of Anti-Infective Therapy</i> , 2003 , 1, 389-401	5.5	7
38	Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1827-33	7	28
37	Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). <i>Cmaj</i> , 2003 , 168, 1671-4	3.5	12
36	Individualized therapy for the treatment-experienced patient. <i>Aids Reader</i> , 2003 , 13, S11-5		1
35	A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. <i>New England Journal of Medicine</i> , 2002 , 346, 1119-26	59.2	314
34	Clinical problem-solving. Where are you from?. <i>New England Journal of Medicine</i> , 2002 , 346, 764-7	59.2	4
33	Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?. <i>Journal of the International Association of Providers of AIDS Care</i> , 2002 , 1, 95-103		9
32	Salvage antiretroviral therapy in HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2002 , 3, 81-90	4	15
31	Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies. <i>Clinical Infectious Diseases</i> , 2002 , 34, 658-61	11.6	3
30	A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 392-400	3.1	43
29	Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. <i>Annals of Internal Medicine</i> , 2002 , 137, 734-7	8	23
28	CD36 deficiency induced by antiretroviral therapy. <i>Aids</i> , 2002 , 16, 353-8	3.5	34
27	Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. <i>New England Journal of Medicine</i> , 2002 , 346, 2039-46	59.2	561

26	A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 149-58	6.1	20
25	Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 887-900	1.6	8
24	Valganciclovir. <i>Drugs</i> , 2001 , 61, 1151-1152	12.1	
23	Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001 , 12, 20C-30C		2
22	Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. <i>Aids</i> , 2001 , 15, 1581-4	3.5	11
21	Alitretinoin. <i>American Journal of Clinical Dermatology</i> , 2000 , 1, 315-316	7.1	
20	Human herpesvirus 8 infection of the genital tract of HIV-seropositive and HIV-seronegative women at risk of sexually transmitted diseases. Canadian Women@ HIV Study Group. <i>Aids</i> , 2000 , 14, 1073-5	3.5	2
19	Comparative tolerability of therapies for cytomegalovirus retinitis. <i>Drug Safety</i> , 1999 , 21, 203-24	5.1	13
18	Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. <i>Transplantation</i> , 1999 , 68, 1305-11	1.8	171
17	Does in vitro susceptibility to rifabutin and ethambutol predict the response to treatment of Mycobacterium avium complex bacteremia with rifabutin, ethambutol, and clarithromycin? Canadian HIV Trials Network Protocol 010 Study Group. <i>Clinical Infectious Diseases</i> , 1998 , 27, 1401-5	11.6	20
16	A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998 , 19, 498-505		42
15	Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. <i>Aids</i> , 1998 , 12, 1653-9	3.5	190
14	Long-term predictive value of a single cytomegalovirus (CMV) DNA PCR assay for CMV disease in human immunodeficiency virus-infected patients. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 281-3	9.7	2
13	Mycobacterium xenopi infection in patients with human immunodeficiency virus infection. <i>Clinical Infectious Diseases</i> , 1997 , 25, 206-10	11.6	93
12	Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. <i>Aids</i> , 1997 , 11, 1689-97	3.5	51
11	HIV-positive women living in the metropolitan Toronto area: their experiences and perceptions related to HIV testing. The HIV Women@ Study Group. <i>Canadian Journal of Public Health</i> , 1997 , 88, 18-22	3.2	12
10	A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. <i>New England Journal of Medicine</i> , 1996 , 335, 377-83	59.2	253
9	The effect of infection and lag screw fixation on revascularization and new bone deposition in membranous bone grafts in a rabbit model. <i>Plastic and Reconstructive Surgery</i> , 1996 , 98, 338-45	2.7	4

8	Rifabutin-associated uveitis. <i>Annals of Pharmacotherapy</i> , 1995 , 29, 1149-55	2.9	71
7	Evaluation of the Merifluor immunofluorescent assay for the detection of <i>Cryptosporidium</i> and <i>Giardia</i> in sodium acetate formalin-fixed stools. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994 , 19, 89-91	2.9	11
6	The Effect of Infection and Lag Screw Fixation on the Union of Membranous Bone Grafts in a Rabbit Model. <i>Plastic and Reconstructive Surgery</i> , 1994 , 93, 574-581	2.7	5
5	Invasive <i>Aspergillus</i> infections in a pediatric hospital: a ten-year review. <i>Pediatric Infectious Disease Journal</i> , 1993 , 12, 673-82	3.4	124
4	Reactivation and dissemination of blastomycosis complicating Hodgkin's disease: a case report and review of the literature. <i>American Journal of Hematology</i> , 1993 , 43, 129-32	7.1	8
3	25- to 30-nm virus particle associated with a hospital outbreak of acute gastroenteritis with evidence for airborne transmission. <i>American Journal of Epidemiology</i> , 1988 , 127, 1261-71	3.8	116
2	Safety and Efficacy of Preventative COVID Vaccines: The StopCoV Study		1
1	Cognitive remediation group therapy compared to mutual aid group therapy for people aging with HIV-associated neurocognitive disorder: randomized, controlled trial. <i>Social Work With Groups</i> , 1-16	0.7	2